Scientific Programme

Wednesday 8 November 2017

16.00-19.00 Registration opens

16.00-17.00 INGID workshop: The specialist nurse: a vital link between patients and doctors

17.30-19.00 Welcome Session “PIDs: not only a paediatric issue”
Welcome – Mrs Jose Drabwell and Prof Steve Holland
• A Historical Perspective on Primary Immunodeficiencies – Prof Helen Chapel
• Importance of adult diagnosis and treatment: case study examples – Dr Siobhan Burns: Gain-of-function mutations, CVID
• PIDs in adulthood: an epidemiological perspective – Dr Charlotte Cunningham Rundles
• Why do we need transition care? Physician Perspective – Dr Nizar Mahlaoui; Patient Perspective – Ms Rachel Hammond

19.00 Welcome Reception

Thursday 9 November 2017

9.00-17.00 Exhibition, Poster section and Registration

8.30-9.15 Opening session including keynote address
Chair: Prof Bobby Gaspar
• Welcome remarks – Mr Johan Prevot
• Congress Opening Address – Mrs Jose Drabwell
• Keynote lecture: Why should we treat Primary Immunodeficiencies at all? – Prof Steven Holland

9.15-10.45 Session 1: Screening for PIDs: early detection for optimal care
Chair: Prof Alain Fischer
• The importance of newborn screening for PIDs: TRECs/KRECs and beyond – Prof Mirjam van der Burg
• An Update from the National SCID NBS French pilot study – Dr Marie Audrain
• Focus on Asia – Middle East: the role of neonatal screening – Dr Mehdi Adeli
• The preventive role of pre-implantation diagnosis – Pro’s and Con’s – Ms Alison Lashwood

10.45-11.15 Coffee Break

11.15-12.30 Session 2: PID care and ethical issues– what can be said, what should be said?
Chair: Prof Bobby Gaspar
• Presentation of case scenarios
• Panel discussion: Dr James Taylor, Prof Alain Fischer, Mrs Jose Drabwell, Mr Bruce Lim, Nurse Carla Duff
• Interactive Discussion – ALL

12.30-14.00 Lunch & Poster Walk

14.00-15.30 Session 3: Regional clinical priorities
Chairs: Mrs Marcia Boyle and Prof Surjit Singh
• EU Regional Priorities – Dr Isabelle Meyts
• USA Regional Priorities – Dr Charlotte Cunningham-Rundles
• Asian Regional Priorities – Dr Adli Ali
• Middle East Regional Priorities: (TBA) – Dr Mehdi Adeli; Disseminated BCGitis in PID – Dr Daifulah Al Zahrani
• LATAM Regional Priorities – Dr Beatriz Carvalho
• African Regional Priorities – Dr James Chipeta

15.30-16.00 Coffee Break

16.00-17.30 Session 4 – PIDs and dermatological issues
Chair: Dr Suleiman Al-Hammadi
• Genetic predispositions to dermatological manifestations in PIDs – Dr Bodo Grimbacher
• Recognizing dermatological issues to accelerate diagnosis and treatment of PIDs – Dr Arti Nanda
• Management of chronic fungal and parasitic skin infections in PIDs – Dr Vas Novelli
• Patient testimony – Mr Andrea Gressani

20:00 Congress dinner: Venue TBA

Friday 10 November 2017

9.00-17.00 Exhibition, Poster section and Registration

9.00-10.30 Session 5: Focus on Immune Dysregulations
Chair: TBC
• The cross-road between PIDs and allergy – Prof António Condino Neto
• Granulomas in PIDs: clinical management and key considerations – Prof Martin Van Hagen
• PIDs and Autoimmune diseases – treatment options – Prof Alain Fischer
• HLH – genetic predisposition and management – Dr Despina Moshous

10.30-11.00 Coffee Break

11.00-12.00 Session 6 – Diseases specific case study session
Chair: Prof Olivier Hermine
• Combined Immunodeficiencies – Prof Aziz Bousfiha
• Antibody deficiencies – Dr Waleed Al Herz
• Innate immunodeficiencies – Dr Jordan Orange

12.00-14.00 Lunch and Poster Walk – (Prayer room available during this time)

12.00-12.30 Lunch session: Oral presentations (poster winners)

14.00-15.15 Session 7: PIDs and Transplant Advances – where are we going?
Chair: Prof Bobby Gaspar
• HSCT – advances in conditioning and graft engineering. Experience from the Middle East Region – Prof Saleh Al Muhsen
• Gene therapy – where are we now? – Prof Alessandro Aiuti
• Gene editing: precision medicine for PIDs – Dr Matthew Porteus
• Patient testimony – HIES: A Fascinating Journey: Ms Eva Varga

15.15-15.45 Coffee Break

15.45-17.15 Session 8: Novel treatments for Primary Immunodeficiencies
Chair: Prof António Condino Neto
• Targeted PID Treatment: The role of monoclonal antibodies – Prof Steve Holland
• Biosimilars: understanding their use in PIDs and the implications – Prof Eric Oksenhendler
• Clinical use of specific inhibitors in the treatment of PIDs – Prof Olivier Hermine
• An overview of latest IG therapy advances – Prof Klaus Warnatz

17.15-17.35 Closure talk: PIDs & Immunology, driving the future of Science? – Prof J.L. Casanova